GlassScriptPhysician profile
Milan G Kahanda
NPI 1811301740
$44,764.08
in general payments reported to CMS, 2019-2025
17 companies · $3,751 in 2025
The $3,751 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20K · 2021: $12K · 2022: $2,822 · 2023: $3,042 · 2024: $3,309 · 2025: $3,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,467 · Food and Beverage: $4,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,467.11 |
| Food and Beverage | $4,635.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,631.59 | 2020-2025 | Aveir, Amplatzer Amulet, Gallant |
| Medtronic Vascular, INC. | $12,500.00 | 2020 | |
| Medtronic, INC. | $7,927.43 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $6,210.03 | 2021-2025 | Ingevity+, Accolade Sr, Watchman Access System |
| Medical Device Business Services, INC. | $2,753.88 | 2022-2024 | Carto 3 |
| Biosense Webster, INC. | $2,039.45 | 2021-2025 | Carto 3, Qdot Micro Catheter, Octaray Mapping Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $218.10 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $141.93 | 2024-2025 | Eliquis |
| Atricure, INC. | $136.09 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Sanofi-Aventis U.S. LLC | $53.48 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $35.99 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $27.05 | 2022-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.18 | 2023 | Jardiance |
| Pfizer INC. | $20.88 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.41 | 2024 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $13.87 | 2025 | Opsynvi, Uptravi |
| Novartis Pharmaceuticals Corporation | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Kahanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.